Zomedica grants 1.82M stock appreciation rights
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Zomedica Corp. (ZOMDF) director Christopher Ross Macleod was granted 1,823,107 stock appreciation rights on November 16, 2026. The rights become exercisable on November 15, 2027, and expire on November 15, 2036.
Insider Trade Summary
Grant/Award: 1,823,107 shares
Grant/Award
1 txn
Insider
MACLEOD CHRISTOPHER ROSS
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Appreciation Right | 1,823,107 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Appreciation Right — 1,823,107 rights (Direct)
Holdings Before and After:
Stock Appreciation Right, 0 to 1,823,107 rights (Direct)
Key Figures
Stock appreciation rights granted: 1,823,107 rights
Exercise price: $0.10 per share
Underlying common shares: 1,823,107 shares
+2 more
5 metrics
Stock appreciation rights granted
1,823,107 rights
Granted November 16, 2026; reported resulting position was 1,823,107 rights
Exercise price
$0.10 per share
Applies to the stock appreciation rights
Underlying common shares
1,823,107 shares
Shares underlying the stock appreciation rights
Exercise date
November 15, 2027
Date the rights become exercisable
Expiration date
November 15, 2036
Expiration date of the rights
Key Terms
Stock Appreciation Right, exercise price
2 terms
Stock Appreciation Right technical
"the grant of 1,823,107 stock appreciation rights"
A stock appreciation right (SAR) is a form of employee pay that gives the holder the right to receive the increase in a company's share price over a set reference price, paid in cash or shares, without having to buy stock first. It matters to investors because SARs can create future cash outflows or dilute existing shareholders if settled in stock, and they align employee incentives with share-price performance like a bonus tied to a home's price rise.
exercise price financial
"the rights have a $0.10 exercise price"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Zomedica director Christopher Ross Macleod receive?
Christopher Ross Macleod received 1,823,107 stock appreciation rights on November 16, 2026. They are tied to 1,823,107 underlying common shares, have a $0.10 exercise price, become exercisable on November 15, 2027, and expire on November 15, 2036.
AI-generated analysis. How Rhea-AI works. Not financial advice.